Abeona Therapeutics Inc.held a successful Type B meeting with the US FDA to align with the Agency on the company’s proposal regarding co-primary endpoints for the pivotal Phase III VIITAL™ study of EB-101 in recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder where those inflicted have a defect in the COL7A1 gene, leaving them unable to produce functioning type VII collagen which is necessary to anchor the dermal and epidermal layers of the skin.